Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria:

≥18 years and ≤75 years in age
Patients with relapsed or refractory AML
No more than one prior stem cell transplant
Has not received the chemotherapy regimen to be used for induction on this trial
Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial

Exclusion Criteria:

Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
Active signs or symptoms of CNS involvement by malignancy.
Stem cell transplantation ≤4 months prior to dosing.
Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
Inadequate organ function.
Abnormal liver function.
Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
Clinically significant cardiovascular disease.
Major surgery within 4 weeks of dosing.